Biotech M&A Fever: Eli Lilly's Bold Bets Spark Retail Trader Excitement for Sellas and ImmunityBio

Well, it seems the biotech world is absolutely buzzing right now, and for good reason! Eli Lilly, a pharmaceutical giant, has truly set tongues wagging with its latest move: an agreement to snap up the privately held Merida Biosciences. We're talking about a deal potentially worth a whopping $2.875 billion in cash – and here's the kicker – Merida's lead candidate, MER511, is only in Phase 1 development for conditions like Graves' disease and thyroid eye disease. It’s a bold bet, to say the least, and it’s got retail traders everywhere bracing for what they’re calling an "M&A rampage."

This isn't Lilly's first rodeo this year, either. The company has been on quite the acquisition tear in 2026, including a $1.2 billion purchase of Ventyx Biosciences and an agreement to acquire Orna Therapeutics for up to $2.4 billion. It paints a clear picture: Lilly is aggressively looking to bolster its pipeline, even at early stages. This kind of investment in nascent projects is what really turns heads, especially among those who track promising smaller biotechs.

And speaking of promising smaller biotechs, the ripple effect from Lilly's significant investment is already being felt. Take Sellas Life Sciences (SLS), for instance. This company has been an absolute standout, with its stock rocketing an incredible 595% over the past year and tacking on another 41% just in August. Their lead candidate, Galinpepimut-S (GPS), is currently in a crucial Phase 3 Regal trial for acute myeloid leukemia (AML), and we’re reportedly just two events away from triggering the final analysis. CEO Angelos Stergiou and his team are targeting a median overall survival of 12.6 months for GPS, compared to eight months for the control arm – that’s a pretty significant improvement if they hit it. Plus, they’ve got SLS009, another intriguing asset for AML and lymphomas, holding some important designations like Fast Track. It’s no wonder the message volume for SLS among retail traders has been high, with many eyeing its potential amidst this M&A fever.

Then there's ImmunityBio (IBRX), another name that’s certainly making waves. Their stock has surged 240% over the last year, with a healthy 14% gain in August alone. Their lead candidate, Anktiva, already boasts authorizations in 34 countries. But the real buzz is around an upcoming FDA decision expected by January 6, 2027, for a U.S. bladder-cancer label expansion specifically for papillary-only bladder tumors. This potential expansion could be a huge catalyst. One IBRX user on Stocktwits summed up the prevailing mood perfectly: "Eli Lilly ponying up $3B for a private immunology company with a lead drug, MER511, only in Phase 1 should put a charge in biotechs." It highlights how deeply this deal resonates across the sector, validating early-stage pipelines.

Indeed, the sentiment isn't just about direct comparison. As one SLS user pointed out, "$SLS $LLY bought Merida Bio today for $2.85B (more than all of SLS) based on PH1B trial data..." This perspective underscores a key takeaway for many retail investors: if a major player like Lilly is willing to pay nearly $3 billion for a company with a Phase 1 asset, it implies a potentially significant re-evaluation of what other promising, more advanced biotech companies, like Sellas or ImmunityBio, might be worth. It’s creating a potent mix of anticipation and excitement, suggesting we might just be at the beginning of a fascinating period for biotech mergers and acquisitions. Keep your eyes peeled!